Evelo Biosciences

Evelo Biosciences

Evelo Biosciences

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials.
Type
B2b
Raised
$217.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$85,000,000
IPO - 2018
$47,500,000
Venture capital - 2018
Team Size
2
Employees
$85,000,000 IPO
Xconomy , PE HUB

Evelo IPO Raises $85M for Microbiome Drugs in Inflammation, Cancer

Health Funding Science
$47,500,000 Venture capital
CrunchBase

Evelo Biosciences Raises $47.5M In New Funding, SEC Filing Indicates News

Funding Science Health
$50,000,000 Venture capital (Series B)
prnewswire , MedCity News

Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team

$35,000,000 Venture capital (Series A)
PE Hub

PE HUB | Evelo Therapeutics racks up $35 mln